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Abstract
Reports on real-world experience on efficacy of bezlotoxumab (BEZ) has been lacking thus far. We retrospectively studied the
efficacy and safety of BEZ in preventing the recurrence of Clostridium difficile infection (CDI) in five university hospitals in
Finland. Seventy-three percent of our 46 patients remained free of recurrence in the following 3 months and the performance
remained as 71% effective also among immunocompromised patients. In severe CDI, BEZ prevented recurrence in 63% of cases.
From our study patients, 78% had three or more known risk factors for recurrence of CDI. Eight of our patients were waiting for
fecal microbiota transplantation but after stopping the antibiotics that were continued to prevent recurrence of CDI and after
receiving BEZ, all remained free of recurrence and did not need the procedure. Success with BEZ as an adjunctive treatment in
preventing recurrence of CDI in high-risk patients may be rated as high. Among a subgroup of our patients, those already
evaluated to be in need of fecal microbiota transplantation, BEZ seems to be an alternative option.
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Introduction
Following a primary episode of Clostridium difficile infection
(CDI), roughly 25% of patients treated with metronidazole or
vancomycin will have a recurrent CDI (rCDI) in subsequent
3 months, most frequently in 2 to 3 weeks after cessation of
the initial treatment regimen. After the first recurrence, the rate
of rCDI increases to about 45% [1–4]. Fidaxomicin has shown
to reduce the rate of rCDI to about 15–20%, even for those
with a previous history of rCDI [5–7]. However, also all of the
abovementioned antibiotics alter the normal gut microbiome
and decrease colonization resistance against C. difficile [8].
Known risk factors for rCDI are age > 65 years, compromised
immunity, severe CDI, prior CDI episode(s), and infection
with hypervirulent ribotypes, hospitalization, inflammatory
bowel disease, renal (or hepatic) impairment, antibiotic use
during standard of care (SOC), antibiotic use after SOC in
3 months, and use of proton pump inhibitors [7, 9–14].
Thus far, fecal microbiota transplantation (FMT) has been
shown to be the most effective treatment for rCDI [15, 16].
However, FMT is not available everywhere for different rea-
sons, and all patients are not eligible for the procedure. Other
treatment options are still needed.
Bezlotoxumab (BEZ) is a fully humanized monoclonal an-
tibody against C. difficile toxin B and indicated for prevention
of rCDI in at-risk patients [17, 18]. The efficacy and safety of
BEZwere investigated among adults in global trials MODIFY
I and MODIFY II in 2011–2015 [19]. In both studies, BEZ
significantly reduced (p < 0.001) rCDI and had a favorable
safety profile. Real-world performance of BEZ has been
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unknown since reports of new studies after launching of this
immunological treatment given in combination with antibac-
terial drug treatment have been lacking thus far. The drug
became commercially available for clinical use in February
2017. We now report our experience in Finnish university
hospitals on the use of BEZ in first 46 patients with real-
world comorbidities and risk for rCDI.
Materials and methods
We investigated retrospectively the efficacy and safety of BEZ
in an intent-to-treat setting in all (five) university hospitals in
Finland (in Helsinki, Kuopio, Oulu, Tampere, and Turku) in
2017. The study was retrospective and therefore no uniform
criteria on the degree of risk was set, but each clinician indi-
vidually weighed the risks before making the decision to give
BEZ in addition to standard of care (SOC). All hospitals used
polymerase chain reaction (PCR) method to detect the gene
for toxin production.
Renal impairment was defined with a background serum
creatinine value more than 133 μl/l or 1.5 times the premorbid
level or hemodialysis. Hepatic impairment was defined as hav-
ing two or more of the following: an albumin level of 3.1 g/dl
or lower, an alanine aminotransferase level at least 2 times the
upper limit of the normal range, a total bilirubin level at least
1.3 times the upper limit of the normal range, or mild, moder-
ate, or severe liver disease (as reported on the Charlson Index).
The study was retrospective and included the first 46 pa-
tients to receive BEZ in Finland in April–December 2017.
Hospitalized patients as well as those who already were
discharged from hospital were accepted for analysis. From
patient records, we collected data on background diseases,
immunosuppression, past CDIs, and severity (based on Zar
score) [19] of the last CDI before the treatment with BEZ.
Also, antibiotics other than for CDI were recorded during
SOC and in 3 months after SOC. The dose of intravenous
BEZ was 10 mg/kg in all but one patient weighing 149 kg,
who got an infusion with 1000 mg only. BEZ was adminis-
tered on 0–7 days after the initiation of SOC with the excep-
tion of those patients who were waiting for FMT. Subsequent
data from 3 months after BEZ treatment was gathered from all
patients. The information about rCDIs and other relevant in-
formation including antibacterial treatments given to the pa-
tients afterwards were collected from patient records and elec-
tronic pharmacy records.
Results
In Helsinki University Hospital, BEZ was given to four hos-
pitalized patients (inpatients, mean age 46 years) and to nine
patients who came from home to get the infusion (outpatients,
mean age 53 years). Table 1 presents different characteristics
of the patients. Eight of the outpatients were waiting for fecal
microbiota transplantation (FMT) after having had several (3
in five, 4 in two, and 2 in one patient) episodes of CDI and
estimated to have a high risk of rCDI. All of these patients
were on different dosages of oral vancomycin treatment be-
fore getting BEZ, but the treatment was discontinued on the
day of the BEZ infusion. One patient with heart transplant was
treated simultaneously with both FMT and BEZ. None of the
eight patients waiting for FMT had a recurrent episode of CDI
in 3 months after the treatment with BEZ—despite four of
them were immunosuppressed. Therefore, the FMT was not
needed anymore for these patients. From the four inpatients,
three were immunocompromised and three had severe CDI
(based on Zar score). One of these four had a rCDI. One
outpatient was treated with BEZ twice—but still relapsed
thereafter. One of the outpatients already had received FMT
but after having rCDI 3 months later, he was successfully
treated with BEZ.
In Kuopio University Hospital, BEZ was given to seven
high-risk patients (mean age 74 years, Table 1). Three of the
patients were immunocompromised. Two of the seven pa-
tients were treated in ICU during the time of BEZ infusion.
In their history, the patients had zero to four (median 2) pre-
vious CDI episodes. Two of the seven patients had a rCDI in
the three following months after BEZ.
In Oulu University Hospital, BEZ was given to five pa-
tients (mean age 71 years, Table 1). One of them was a 97-
year-old woman, living alone in her home, who had the sev-
enth confirmed episode of CDI in 1 year and had already been
treated with metronidazole for 14 days and with oral vanco-
mycin altogether for 94 days before she got the BEZ infusion
and a course of vancomycin for 28 days thereafter. In the
following 3 months, she did not have a rCDI. Another patient
was a 76-year-old patient with angioimmunoblastic T cell
lymphoma, who had the fourth episode of CDI in 1 year.
For the three previous episodes, the treatments were altogether
40 days oral metronidazole and 42 days oral vancomycin. The
fourth episode without recurrence was treated with 14 days
oral metronidazole and BEZ infusion. From the remaining
three cases, one had the fifth episode of CDI but relapsed
again after BEZ, and two had the third episode of CDI without
recurrence after the BEZ.
In Tampere University Hospital, BEZ was given to seven
patients (mean age 71 years, Table 1). Two of them were outpa-
tients with amild clinical picture of rCDI and came from home to
receive the BEZ infusion. They did not get a relapse of CDI in
3 months. Five of the seven patients were hospitalized patients
with severe infection in four of them and background immuno-
suppression also in four of the five patients. Three (all with severe
CDI) of these five patients had a rCDI in 3 months despite BEZ
treatment. One of these patients was diagnosed with hepatic car-
cinoma immediately after the BEZ treatment. The SOC in these
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three patients was vancomycin in all cases. Two of the five in-
patients did not have a relapse although one of them, a hemodi-
alysis patient, did have a long antibiotic treatment for
spondylodiscitis after the BEZ treatment.
In Turku University Hospital, BEZ was given to fourteen
patients, all of them inpatients (mean age 69 years, Table 1).
Ten of the patients were immunocompromised and had several
comorbidities. Three patients had acute leukemia or received
allogenic hematologic stem cell transplantation (HSCT) in the
previous few months. SOC for all of the hematologic patients
included fidaxomicin. These patients were also neutropenic and
continuously treated therefore with antibiotics after the BEZ in-
fusion. Both of the HSCT patients did not have rCDI after BEZ
infusion. Of the fourteen high-risk patients, fivewere treatedwith
BEZ after the first CDI episode, while the number of CDI epi-
sodes was two in five patients, three in two patients, and four in
two patients. Thus, the average number of CDI episodes in this
very high-risk patients was 2.1. Two of the fourteen severely ill
patients died during the following 3 months after the BEZ
treatment—one due to end-stage cardiac disease (5 days after
BEZ infusion), one due to graft-versus-host disease (GVHD)
(1.5 months after BEZ). Ten of the fourteen (71%) patients in
this very high-risk group did not have a rCDI in 3 months after
the BEZ treatment. The last CDI episode in the group of fourteen
patients was severe (based on Zar score) in four patients. None of
these four patients relapsed in 3 months, but one of them died on
GVHD, affecting also the intestine, already before 3 months had
elapsed.
Altogether, 46 patients were treated, in addition to SOC,
with BEZ infusion during April–December in 2017 in all uni-
versity hospitals in Finland. Altogether, 32 (73%) of 44 pa-
tients did not have rCDI in 3 months after BEZ infusion. Two
patients died before 3 months had elapsed after the BEZ
infusion—and thus were not included to the group of “remain-
ing free of rCDI.” One of the patients got the infusion twice
but relapsed again after the second infusion. The mean age of
all patients was 66 years (range 15–97 years). Twenty-two of
the patients were female and 24 were men. The mean number
of episodes of CDI was 2.74 (range 1–7). Seventeen patients
were outpatients (eight of them waiting for FMT procedure)
and 29 of the 46 patients were hospitalized at the time of BEZ
infusion. Twenty-eight (61%) of the 46 patients were immu-
nocompromised due to background comorbidity or
immunosuppressive treatment. Twenty (71%) of the 28 immu-
nocompromised patients did not have a rCDI after the treat-
ment with BEZ. Seven of the 46 patients suffered from hepatic
impairment and twelve from renal impairment. Based on the
Zar score, 18 (39%) patients had severe CDI but the majority
(10 of 16 patients, 63%) of them did not have a rCDI in
3 months after the treatment with BEZ (not eligible in two
patients who died during the follow-up period). During SOC
for the CDI episode, majority (28; 61%) of the high-risk pa-
tients had concomitant antibacterial treatment for another in-
fection than CDI. During the following 3 months after the
BEZ infusion, 19 (42%) of 45 patients (unknown for one
patient) were treated for at least one antibacterial drug (other
than those directed against C. difficile). The risk factors for
rCDI and their frequency are listed in Table 2. Vancomycin
was used in SOC partly or solely in 37 of 46 patients, metro-
nidazole in nine, fidaxomicin in seven, and tigecycline in two.
Adverse effects of BEZ were otherwise not found, but one
patient experienced startling sensations after the infusion and
one patient presented with fever in the following day after the
infusion. The use of BEZ was regarded as safe by the
investigators/treating physicians, since none of the possible
adverse drug reactions had a probable causal relationship to
the BEZ infusion.
Table 1 First 46 patients (pts)
that received bezlotoxumab infu-
sion in Finland in April–
December 2017 (university
hospitals)
Helsinki Kuopio Oulu Tampere Turku
Total number of pts 13 7 5 7 14
Mean age (years) 56 74 71 59 69
Inpts 4 5 2 5 12
Immunocompromised pts 7 3 3 5 10
Severe CID, pts 5 2 2 4 4
Free of rCDI in 3 months, pts (%) 11 (85) 5 (71) 4 (80) 4 (57) 10 (71)
Table 2 Frequency of the number of risk factors present in individual
patients (n = 46) in the entire study population. Risk factors for rCDI
(altogether 8 risk factors) recorded included the following: age >
65 years, compromised immunity, severe CDI, one or more previous
CDI episodes, renal impairment, hepatic impairment, antibiotic use
during SOC, antibiotic use after SOC in 3 months
Risk factors
present
Number of patients,
n = 46 (%)
0 0
1 3 (7)
2 7 (15)
3 7 (15)
4 13 (28)
5 14 (30)
6 2 (4)
7 0
8 0
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Discussion
In MODIFY I and II studies, BEZ demonstrated significant
reductions in CDI recurrence compared with placebo (17% vs
28% in MODIFY I and 16% vs 26% in MODIFY II;
P < 0.001) in adults receiving antibiotic treatment for primary
CDI or rCDI [20]. In the MODIFY I and II, approximately
36% had a single risk factor, approximately 27% had 2 risk
factors, and approximately 12% had ≥ 3 of previously identi-
fied five “high-risk” factors for rCDI: age ≥ 65 years, compro-
mised immunity, severe CDI, prior CDI episode(s), and infec-
tion with ribotypes 027/078/244 [21]. Patients with more than
or equal to three risk factors experienced the greatest reduction
in CDI recurrence with BEZ (− 24.8% [range − 39.1%, −
9.3%]), suggesting a potential targeted patient population for
the drug. One limitation of these data is that several of the risk
factors are loosely defined, including immunocompromised
patients, which was based on clinical criteria [21].
Patients with rCDIs often have extensive number of comor-
bidities and are at very high risk for a new recurrence. We
therefore wanted to retrospectively investigate the real-world
efficacy of BEZ in preventing rCDI. In our study, patients
were often highly immunocompromised and 78% of all pa-
tients had three or more of eight listed (Table 2) risk factors for
recurrence of CDI: 16 (35%) had 5–6 risk factors, 20 (43%)
had 3–4 risk factors, and 10 (22%) had 1–2 risk factors.
Definitions applied to severe CDI come from data from im-
munocompetent hosts and may not be applicable to the pop-
ulation of e.g. HSCT recipients. Severity of CDI in cancer
patients may be underestimated for example due to the fre-
quent presence of neutropenia [22]. Furthermore, patients
with hematologic malignancies have lower creatinine levels
at the time of CDI diagnosis compared with control patients.
Therefore, CDI severity criteria based on white blood cell
count and creatinine level may not be applicable to all patients
[23].
Pooled clinical data from the MODIFY I and II studies
demonstrated frequent use of concomitant antibiotics (37%
in the BEZ arm vs 41% in the placebo arm) within the
follow-up period (defined as the first day after the end of
SOC treatment through onset of rCDI or day 90 following
the infusion of study medication) [24, 25]. Respectively,
42% of patients in our study used concomitant antibiotics
within follow-up period of 3 months. In our experience, the
best results to prevent rCDI were achieved when BEZ was
administered in a stable situation, as for example immediately
before discharging from hospital or when all antibiotic treat-
ments including SOC antibiotics were already discontinued
(as was the case with those receiving BEZ when waiting for
FMT). In this situation, intestinal microbiome gets time for
recovery, contributing to healing. This treatment model is
the same as with FMT, in which the aim is to avoid antibiotics
after transplantation.
BEZ is generally well tolerated and reported adverse
drug reactions did not differ significantly from placebo
in the MODIFY I and II trials [20]. However, an unex-
plained increased risk of heart failure was noted (in
2.2% of BEZ and 0.9% of placebo arm) for patients
with underlying congestive heart failure in phase III
trials [17, 18]. In addition, 19.5% (23/118) and 12.5%
(13/104) of this subgroup died, although the cause of
death varied considerably. Heart failure and deaths were
not infusion-related but occurred throughout the 12-
week follow-up period. Heart failure is listed as warning
and precaution in the US product insert and in these
patients, BEZ should be reserved for use when benefit
outweighs risk [17]. In our study, BEZ was well toler-
ated since we could not note any adverse drug-related
reactions than possible infusion-related adverse reactions
in two patients. However, one of our patients who had
end-stage coronary artery disease and congestive heart
failure died 5 days after BEZ infusion. The treating
physician, however, regarded the succumbing as a natu-
ral event due to background comorbidity.
Clinical experience on BEZ has become from post hoc
analyses of MODIFY I and II trials. The use of BEZ can
reduce CDI-associated readmissions to hospitals especially
in participants with high-risk prognostic factors [26]. The
present real-world data on efficacy of BEZ in prevention of
rCDI in very high-risk patients gives clinicians an estimate on
its performance to compare this immunologic treatment with
other strategies including FMT. However, the availability of
FMT is limited—not all hospitals have resources to efficiently
and timely use it. On the contrary, BEZ is an available treat-
ment option in every hospital and may be offered also to
patients that refuse FMT. Actually, the long-term safety of
FMT is unclear. FMT is not a well-controlled procedure,
whereas BEZ is a regulated medicine. There are also patients
whose comorbid situation is not suitable (e.g., hematologic
patients with neutropenia and/or allogenic transplants) for
the use of FMT.
One limitation of our study is that we used only the
toxin gene PCR for detection of CDI. It is likely that C.
difficile will colonize patients for some time after the
SOC. However, in our hospitals, the threshold to use
the test is high—it is prohibited to use the test without
a real clinical suspicion of CDI or the recurrence of it.
Furthermore, the use of BEZ was always controlled by
an infectious diseases specialist.
In conclusion, real-world experience on BEZ efficacy
seems to be promising in our retrospective study of 46 patients
in a university hospital setting in Finland. BEZ infusion as an
1950 Eur J Clin Microbiol Infect Dis (2019) 38:1947–1952
adjunctive treatment to SOCwas effective in the prevention of
rCDI in 73% of patients and the performance remained as
71% effective also among immunocompromised patients. In
severe CDI, 63% of cases remained free of rCDI in the fol-
lowing 3 months. From our study patients (n = 46), 78% had
three or more known risk factors for recurrence of CDI.
Therefore, success with BEZ together with SOC in preventing
rCDImay be rated as high. Among a subgroup of our patients,
those already evaluated to be in need of FMT, BEZ seems to
be an alternative option.
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